Akinobu Ota

Professor

Kinjo Gakuin University

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Immunology Immunology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (5)

Sivasundaram Karnan

Senior Assistant Professor

Aichi Medical University

JAPAN

View details

Shinobu Tsuzuki

Professor

Aichi Medical University

JAPAN

View details

Kaori Uchino

Aichi Medical University

JAPAN

View details

Hiroyuki Konishi

Professor

Aichi Medical University

JAPAN

View details

Toshinori Hyodo

Senior Assistant Professor

Aichi Medical University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Akinobu Ota

Research Interests

Explore related searches

Contact this professor

Articles (10)

Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma

CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma

PDZ‐binding kinase inhibitor OTS514 suppresses the proliferation of oral squamous carcinoma cells

BCL6 inhibition ameliorates ruxolitinib resistance in CRLF2-rearranged acute lymphoblastic leukemia.

Long noncoding RNA profile of the intracranial artery in patients with moyamoya disease.

Correction of a CD55 mutation to quantify the efficiency of targeted knock-in via flow cytometry.

Flow cytometry-based quantification of targeted knock-in events in human cell lines using a GPI-anchor biosynthesis gene PIGP.

Experimental strategies to achieve efficient targeted knock-in via tandem paired nicking.

Transcriptome-wide analysis of intracranial artery in patients with moyamoya disease showing upregulation of immune response, and downregulation of oxidative phosphorylation and DNA repair.

CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia

Collaborators (5)

Sivasundaram Karnan

Shinobu Tsuzuki

Kaori Uchino

Hiroyuki Konishi

Toshinori Hyodo

Make your next move.